FDA Panel backs approval of Cosentyx

Last week, an advisory panel to the US Food and Drug Administration unanimously backed the use of Novartis' drug, Cosentyx, as a treatment for plaque-psoriasis. The injectable biologic is a member of a class of drugs known as IL-17 inhibitors, which targers the inflammation-causing protein interleukin-17 (IL-17). This class of drug has shown promising success in the treatment of plaque psoriasis. Although the FDA is not obligated to accept the panel's recommendations, it typically does so.